Table 1.

Direct comparisons evaluated in identified RCTs

Direct comparisons relevant to scope included in any NMA (primary or sensitivity for any outcome)	Identified studies evaluating comparison
	Included in a NMA	Omitted from NMA
vs placebo
Cidofovir	Snoeck10	Matteelli8
Imiquimod 5% cream	Arican35 Beutner36 Edwards37 Gilson24 Tyring38	–
Polyphenon E 10% ointment	Stockfleth25 Tatti39	–
Podophyllotoxin 0.5% solution	Beutner40 Kirby41 Von Krogh42	Greenberg43
Electrotherapy	Benedetti Panici22	–
Topical treatments vs each other
Podophyllotoxin 0.5% solution vs podophyllotoxin 0.15% cream	Lacey23 Strand44	Claesson45
Podophyllotoxin 0.5% solution vs imiquimod 5% cream	Komericki46	–
Topical treatment vs ablative treatment
Imiquimod 5% cream vs cryotherapy	Akhavan29 Stefanaki28	Tuncel47
TCAA 80%–90% versus cryotherapy	Abdullah48	–
Ablative treatments vs each other
Cryotherapy vs electrotherapy	Stone49	Simmons27
Cryotherapy vs CO2 laser therapy	Azizjalali50	–
Argon plasma coagulation vs electrotherapy	–	Braga51
CO2 laser therapy vs electrotherapy	–	Ferenczy52
Injectable treatment vs others
Cidofovir vs electrotherapy	Orlando9 Stone49	–
Combination treatment vs monotherapy
Cryotherapy plus podophyllotoxin 0.15% cream vs cryotherapy alone	Gilson26	–
Argon plasma coagulation plus imiquimod 5% vs argon plasma coagulation alone	–	Viazis53
Additional comparisons included to strengthen NMA	Identified studies evaluating comparison
Podophyllotoxin 0.5% solution vs podophyllin 20%–25%	Edwards54 Kar31 Lacey23 Lassus32 Mazurkiewicz55
Podophyllotoxin 0.15% cream vs podophyllin 20%–25%	Lacey23
Imiquimod 5% cream vs podophyllin 20%–25%	Akhavan29 Padhiar33
Cryotherapy vs podophyllin 20%–25%	Akhavan29 Sherrard56 Stone49
Surgical excision vs podophyllin 20%–25%	Jensen30
Electrotherapy vs podophyllin 20%–25%	Stone49

CO₂, carbon dioxide; NMA, network meta-analysis; RCT, randomised controlled trial; TCAA, trichloroacetic acid.